• Hengrui Pharma presented a company-record 64 oncology studies at the ESMO Congress 2026 in Madrid, covering 21 innovative drugs.
• The research included nine marketed products and 12 investigational candidates across more than ten cancer areas.
• As of June 2026, its oncology portfolio included 14 independently developed medicines marketed in China, with around 50 innovative assets in clinical development.
• Innovative oncology medicines generated 81.02% of total innovative medicine sales revenue in 2025, underscoring the business's commercial importance.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jiangsu Hengrui Medicine Co. Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: EN83019) on October 28, 2026, and is solely responsible for the information contained therein.